---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-056135"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2026-02-18T23:59:59+00:00"
generated_at: "2026-05-16T02:09:20.571108+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Sensei Biotherapeutics closes merger with Faeth and $200M PIPE; existing holders diluted to ~4.9%

## Summary
- Issued ~10,602 Series B Preferred shares (each convertible into 1,000 common) to acquire Faeth; pre-PIPE: Faeth holders ~89.3%, Sensei ~10.7%.
- Sold 14,440 Series B Preferred shares in $200M PIPE; post-PIPE: PIPE investors ~54.3%, Faeth ~40.8%, Sensei ~4.9%.
- Anand Parikh (ex-Faeth CEO) appointed as COO and director; granted 1,239,305 option inducement award vesting over 4 years.
- Certificate of Designation filed; conversion of Series B requires stockholder approval and beneficial ownership limits of 4.99%-19.99%.

## SEC filing metadata
- accession: 0001193125-26-056135
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2026-02-18T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 5.03, 2.01, 3.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312526056135/0001193125-26-056135-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312526056135/d112826d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-056135
- JSON: https://secwatch.observer/filing/0001193125-26-056135.json
- Plain text: https://secwatch.observer/filing/0001193125-26-056135.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.